Black Stone Minerals (NYSE:BSM)
Historical Stock Chart
From May 2019 to May 2024
BSD Medical's MRI-Integrated System Precisely Monitors Cancer
Hyperthermia Noninvasively, According to Study Published in Cancer Research
BSD's Groundbreaking Use of Magnetic Resonance Thermography to Identify Vital
Characteristics of Tumors During Treatment is Cover Feature of the July 1st
Issue
SALT LAKE CITY, July 7 /PRNewswire-FirstCall/ -- BSD Medical Corp. (AMEX: BSM)
today announced that Cancer Research, the journal of the American Association
for Cancer Research, has published a landmark review of BSD's successful use of
noninvasive magnetic resonance thermography to measure hyperthermia and other
conditions in cancer during treatment (Cancer Res 2005; 65:(13)). Magnetic
resonance thermography is the couplet technology to the BSD-2000/3D by BSD
Medical, which noninvasively focuses radiofrequency (RF) energy in 3D on
tumors, bringing them to precise therapeutic temperatures and conditions.
Together these technologies are used to increase the effectiveness of radiation
and chemotherapy in killing cancer.
The study involved patients who had previously received radiation and
experienced recurrent rectal cancer. The patients were treated with
chemotherapy combined with deep pelvic hyperthermia using the BSD-2000/3D/MR
located at Charite Medical School in Berlin, Germany. Magnetic resonance
thermography was used in conjunction with hyperthermia therapy to generate a
series of three-dimensional pictures that enabled physicians to determine tumor
temperature and other important tumor traits.
The successful use of magnetic resonance thermography in combination with deep
regional hyperthermia cancer therapy has long been considered a crucial
breakthrough for the treatment of many deep cancers. Dr. Peter Wust, lead
researcher in using BSD Medical's system at the school said, "The benefits of
superficial hyperthermia treatment in combination with radiation or
chemotherapy are well-known in the oncology community. However, one ongoing
issue concerning deep regional hyperthermia is the ability to precisely monitor
the various heating zones in the tumor, ensuring that surrounding tissue is
largely unaffected."
This research has demonstrated that noninvasive magnetic resonance thermography
may be successfully used to monitor tumor temperature and other important
measurements with the effective use of deep regional hyperthermia therapy of
the pelvis. Vivid, color reproductions of the magnetic resonance thermography
images created by the BSD-2000/3D/MR appear both on the cover of Cancer
Research and in the nine-page article published in this issue. The system used
at this location was developed through the collaboration of the engineering
groups at BSD Medical Corporation and Siemens Medical Systems.
About Hyperthermia
Hyperthermia, or the elevation of tumor temperature through the use of
RF/microwave energy, helps address the limitations of radiotherapy and
chemotherapy for many patients with cancer. Hyperthermic temperatures kill
cancer cells and increase blood and oxygen circulation within the tumor,
breaking down the tumor's resistance to radiation and to permeation by drugs.
The benefits of hyperthermia as an anti-cancer modality have been demonstrated
in numerous published research papers and also in clinical practice. A study
published in the May 2005 issue of the Journal of Clinical Oncology illustrates
the benefits of hyperthermia with radiation therapy for the treatment of chest
wall recurrence. Conducted by researchers at Duke University Medical Center,
the study showed that radiation treatment with hyperthermia resulted in
improved local tumor control and demonstrated a particular benefit for patients
who had previously received radiation therapy, as more than two-thirds of these
patients experienced total disappearance of their tumors.
About BSD Medical
BSD Medical Corporation is a leading developer of systems that employ focused
microwave/radiofrequency energy to treat diseases and other medical conditions,
including cancer, by creating precisely elevated temperatures within the
diseased site, as required by a number of medical therapies. BSD Medical is the
winner of the 2005 Frost and Sullivan Technology of the Year Award for cancer
therapy devices. For more information about BSD Medical Corporation and its
therapies, visit http://www.bsdmc.com/.
Statements contained in this press release that are not historical facts are
forward-looking statements, as that item is defined in the Private Securities
Litigation Reform Act of 1995. All forward-looking statements, including all
projections and forecasts of future sales based on these or other findings, are
subject to risks and uncertainties, some of which are detailed in part in the
Company's filings with the Securities and Exchange Commission.
Contacts:
Wendy Williams / Jon Siegal
Schwartz Communications
(781) 684-0770
DATASOURCE: BSD Medical Corp.
CONTACT: Wendy Williams and Jon Siegal both for BSD Medical
Corporation, +1-781-684-0770,
Web site: http://www.bsdmc.com/